FMP
Virtus LifeSci Biotech Products ETF
BBP
AMEX
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
53.37 USD
-3.2876 (-6.16%)
Uh oh, It looks like we don't have these records, but don't worry we're trying to source them!